US2224256A - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation Download PDF

Info

Publication number
US2224256A
US2224256A US223204A US22320438A US2224256A US 2224256 A US2224256 A US 2224256A US 223204 A US223204 A US 223204A US 22320438 A US22320438 A US 22320438A US 2224256 A US2224256 A US 2224256A
Authority
US
United States
Prior art keywords
salicylic acid
pharmaceutical preparation
magnesium carbonate
acetyl salicylic
normal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US223204A
Inventor
William N Doushkess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avantor Performance Materials LLC
Original Assignee
JT Baker Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JT Baker Chemical Co filed Critical JT Baker Chemical Co
Priority to US223204A priority Critical patent/US2224256A/en
Application granted granted Critical
Publication of US2224256A publication Critical patent/US2224256A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10Carbonates; Bicarbonates

Definitions

  • the present invention relates to pharmaceutical preparations, and especially to medicinal preparations for internal use.
  • An object of the invention is the increase in 5 effectiveness of a given dose, or, alternatively, the accomplishment, by means of the invention, of the same therapeutic effect with a smaller 7 dose, of a known medicinal agent, as described below.
  • the invention resides in the provision of new compositions of matter in the pharmaceutical field, with particular reference to medicines for internal use.
  • acetyl salicylic acid aspirin
  • they may, according to the present invention, be made up to contain 3.6 grains of acetyl salicylic acid and 2 grains of normal magnesium carbonate, which tablets have substantially the same therapeutic eiIect as the hitherto known tablets containing K grains of acetyl salicylic acid made up without the normal ma nesium carbonate.
  • compositions may be made by mixing equal'molecular weights of normal magnesium carbonate and acetyl salicylic acid, although it will be understood that so far 30 as the present invention is concerned, one or the other may be predominant.
  • ingredients, well pulverized, are thorough- 1y mixed mechanically, are in a dry state and thereafter, with or without a binder, may be sent to the tablet machine.
  • a binder such as asugar or gum may be used or starch" may be used as a binder and tablet-disintegrating agent.
  • Magnesium sulfate solution may be mixed with an equivalent amount of sodium bicarbonate so- 20 lution, this mixture being allowed to stand several days in acool place. Small crystals of normal magnesium carbonate will settle out or solution and these may then be filtered, washed and. dried.
  • acetyl salicylic acid tab- 25 lets made up as above described have to a marked extent the characteristic of solubility.
  • the increase in therapeutic effect is due not merely to the slight laxative action of the normal mag 0 nesium carbonate but is due in large part to the ready solubility of the tablet.
  • What is .claimed is A therapeutic mixture including normal magnesium carbonate and acetyl salicylic acid.

Description

Patented Dec. 10, 1940 g UNITED STATES PATENT OFFICE.
PHARMACEUTICALTREPARATION No Drawing; Application August 5, 1938, Serial No. 223,204
1 Claim. (Cl. 167-455) The present invention relates to pharmaceutical preparations, and especially to medicinal preparations for internal use.
, An object of the invention is the increase in 5 effectiveness of a given dose, or, alternatively, the accomplishment, by means of the invention, of the same therapeutic effect with a smaller 7 dose, of a known medicinal agent, as described below.
10 The invention resides in the provision of new compositions of matter in the pharmaceutical field, with particular reference to medicines for internal use.
As a practical example of the invention, it may be used as follows in the compounding of acetyl salicylic acid (aspirin) tablets. Where such tablets have hitherto been made up to contain a five grain dose, they may, according to the present invention, be made up to contain 3.6 grains of acetyl salicylic acid and 2 grains of normal magnesium carbonate, which tablets have substantially the same therapeutic eiIect as the hitherto known tablets containing K grains of acetyl salicylic acid made up without the normal ma nesium carbonate.
In general, satisfactory compositions may be made by mixing equal'molecular weights of normal magnesium carbonate and acetyl salicylic acid, although it will be understood that so far 30 as the present invention is concerned, one or the other may be predominant.
The ingredients, well pulverized, are thorough- 1y mixed mechanically, are in a dry state and thereafter, with or without a binder, may be sent to the tablet machine. If desired, a binder such as asugar or gum may be used or starch" may be used as a binder and tablet-disintegrating agent.
It will be understood, of course, that there is nothing critical in the proportions above given; they are stated by way of specific examples in the practice of the invention, which resides broadly in mixing normal magnesium carbonate 5 with acetyl salicylic acid. It is also to be observed that the invention provides not only a means broadly of increasing the therapeutic effect of a given dose, but also a means of forming, with the primary therapeutic agent, a mag- 10 nesium compound which in itself and specifically makes the composition more active therapeutically.
While the invention is not concerned with the particular method of preparing the normal magnesium carbonate (as distinguished. from the light and from the heavy magnesium carbonate) it may be made by the following known method. Magnesium sulfate solution may be mixed with an equivalent amount of sodium bicarbonate so- 20 lution, this mixture being allowed to stand several days in acool place. Small crystals of normal magnesium carbonate will settle out or solution and these may then be filtered, washed and. dried.
It will be noted that acetyl salicylic acid tab- 25 lets made up as above described have to a marked extent the characteristic of solubility. Thus the increase in therapeutic effect is due not merely to the slight laxative action of the normal mag 0 nesium carbonate but is due in large part to the ready solubility of the tablet.
What is .claimed is A therapeutic mixture including normal magnesium carbonate and acetyl salicylic acid.
wnmm if. nousnxnss.
US223204A 1938-08-05 1938-08-05 Pharmaceutical preparation Expired - Lifetime US2224256A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US223204A US2224256A (en) 1938-08-05 1938-08-05 Pharmaceutical preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US223204A US2224256A (en) 1938-08-05 1938-08-05 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
US2224256A true US2224256A (en) 1940-12-10

Family

ID=22835512

Family Applications (1)

Application Number Title Priority Date Filing Date
US223204A Expired - Lifetime US2224256A (en) 1938-08-05 1938-08-05 Pharmaceutical preparation

Country Status (1)

Country Link
US (1) US2224256A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447396A (en) * 1946-05-17 1948-08-17 Coplans Myer Preparation of stable medicinal salts of acetylsalicylic acid
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US20030056233A1 (en) * 1998-12-09 2003-03-20 Rolf Ehrhardt Method of treating psoriasis using anti-gamma interferon antibody

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2447396A (en) * 1946-05-17 1948-08-17 Coplans Myer Preparation of stable medicinal salts of acetylsalicylic acid
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US20030056233A1 (en) * 1998-12-09 2003-03-20 Rolf Ehrhardt Method of treating psoriasis using anti-gamma interferon antibody

Similar Documents

Publication Publication Date Title
US4198391A (en) Pharmaceutical compositions
US3773920A (en) Sustained release medicinal composition
EP0011489B1 (en) An analgesic effervescent powder and process for its preparation
JP2016065086A5 (en)
PT71727A (en) Process for preparing a pharmaceutical composition particularly suitable for cancer treatment
KR850000975A (en) Compositions based on mixtures of valproic acid and salts thereof
US2211485A (en) Effervescent acetyl salicylic acid
JPS5948415A (en) Long time active matrix tablet
US2224256A (en) Pharmaceutical preparation
US3008874A (en) Pharmaceutical compositions
ES370058A1 (en) Antibiotic compositions
CS203036B2 (en) Process for preparing 1,3-dibenzoyloxy-17alpha-ethinyl-7alpha-methyl-1,3,5/10/-estatrien-17beta-ole
US3036954A (en) Analgesic compositions
CA1095411A (en) Cardiotonic gelatin capsules
US2847346A (en) Laxative compositions contaqining dioctyl sodium sulfosuccinate and 1, 8-dihydroxyanthraquinone
US3068147A (en) Analgesic compositions containing o-propoxybenzamide with salicylamide or acetyl-p-aminophenol or mixtures thereof
US2411636A (en) Stabilized ferrous sulfate
US2910403A (en) Anti hypertensive compositions comprising 2-methyl-5, 8-dimethoxychromone and acetamides
US3024165A (en) Effervescent acetyl-salicylic acid tablet
US2799619A (en) Anti-excitatory compositions
US2918485A (en) Dihydroxy aluminum salicylates
US2128741A (en) Amine hydriodides
US2748052A (en) Therapeutically active compositions containing amphetamine
US3348999A (en) Compositions to enhance the learning rate and retention level in animals comprising 2-imino-5-phenyl-4-oxazolidinone and a relatively insoluble base
US2995598A (en) Beta(ortho-acetoxyphenyl)propionic acid and salts thereof